CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 13 enrolled
Drug / intervention
Intravenous infusions of Xynthadrug
Likely dose
Intravenous infusions of Xyntha 50IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02461992
NCT02461992Phase 1Completed
CompareCT.gov

An Open-label, Single Dose Pharmacokinetic Study Of Xyntha (Moroctocog Alfa (Af-cc), Recombinant Factor Viii) In Male Chinese Subjects With Hemophilia A

Pfizer·interventional·Posted Jun 3, 2015·Updated Sep 7, 2016

In Brief

A Phase 1 clinical trial evaluating Intravenous infusions of Xyntha for Hemophilia A. Completed, enrolled 13 participants across 2 sites.

Detailed Summary

An open-label, single dose pharmacokinetic study of Xyntha (Moroctocog Alfa (AF-CC), Recombinant Factor VIII) in male Chinese subjects with hemophilia A

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHemophilia A
CountriesChina
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 3, 2015
Enrollment StartJul 1, 2015
Primary CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 11.1 years ago

Interventions

Intravenous infusions of Xynthadrug

A single dose 50IU/kg dose of Xyntha administered by intravenous infusion within 10 minutes on Day 1